Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a double-blind placebo-controlled RSV challenge study of ALS-008176
2013-004036-30Phase 2Completed
- Sponsor
- Alios BioPharma
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing ALS-008176 with Placebo (2 arms). Primary endpoint: Reduction in RSV viral load AUC0-t. Started Oct 2013; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2013-004036-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004036-30.